Covered recipient · General Payments record
LATISHA D HEINLEN
Allopathic & Osteopathic Physicians Internal Medicine Rheumatology
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
Saved only in this browser. No account or alerts.
General Payments · PY2024 · Entire year
$115,061.59
294 records · 0 disputed
“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”
— Centers for Medicare & Medicaid Services, Open Payments
A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.
These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
How these totals are calculated
- This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Methodology & Data — sourcing, labeling, and limitations.
Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗
By nature of payment
PY2024 · entire year · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $84,470.00 | 29 |
| Consulting Fee | $16,419.00 | 5 |
| Travel and Lodging | $7,695.32 | 26 |
| Food and Beverage | $6,378.27 | 233 |
| Education | $99.00 | 1 |
By paying entity
PY2024 · entire year · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $40,715.78 | 77 |
| Janssen Biotech, Inc. | $37,586.20 | 57 |
| GENZYME CORPORATION | $25,359.50 | 28 |
| UCB, Inc. | $9,653.79 | 41 |
| Amgen Inc. | $498.57 | 31 |
| AstraZeneca Pharmaceuticals LP | $471.02 | 19 |
| Novartis Pharmaceuticals Corporation | $210.29 | 11 |
| Lilly USA, LLC | $120.30 | 6 |
| E.R. Squibb & Sons, L.L.C. | $119.31 | 6 |
| Fresenius Kabi USA, LLC | $85.77 | 4 |
| GlaxoSmithKline, LLC. | $84.03 | 5 |
| Aurinia Pharma U.S., Inc. | $62.54 | 3 |
| PFIZER INC. | $34.06 | 2 |
| Sandoz Inc. | $15.72 | 1 |
| Genentech USA, Inc. | $15.71 | 1 |
| Alexion Pharmaceuticals, Inc. | $15.26 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $13.74 | 1 |
Page 2 of 6; records 51–100 of 294 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.
IndustryPayments · General Payments
LATISHA D HEINLEN
NPI 1649430810 · CMS profile ID 1235381
Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology
OKLAHOMA CITY, OK
A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.
A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.
General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types
Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00
Page 2 of 6; records 51–100 of 294 matching records. This page contains 50 records (maximum 50), not the full filtered export.
Filtered page: https://industrypayments.org/provider/npi-1649430810?year=2024&recipient=provider&page=2#records-h
CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff
Cite these filtered records
The citation includes this program year, filters, data edition, and page of results.
- Plain
- LATISHA D HEINLEN, NPI 1649430810, CMS profile ID 1235381. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 294 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1649430810?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- APA 7
- IndustryPayments. (2026). LATISHA D HEINLEN, NPI 1649430810, CMS profile ID 1235381. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 6; records 51–100 of 294 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1649430810?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
- Bluebook
- LATISHA D HEINLEN, NPI 1649430810, CMS profile ID 1235381, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 6; records 51–100 of 294 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1649430810?year=2024&recipient=provider&page=2#records-h.
Centers for Medicare & Medicaid Services, Open Payments
Citation formats are provided for reference; check the requirements of your publication.
Payment records · PY2024
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30
294 matching records · $115,061.59 reported total · 0 disputed
Nature of payment: All payment types
Records imported here (UTC).
CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.
Showing records 51–100 of 294.
| Paying entity | Amount | Date | Nature of payment | Dispute status | Publication flags | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|---|
| UCB, Inc. | $158.98 | 10/25/2024 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155582459 | CMS |
| UCB, Inc. | $333.16 | 10/25/2024 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155582461 | CMS |
| UCB, Inc. | $350.75 | 10/25/2024 | Travel and Lodging | No dispute reported | Delay: No Change: NEW | 06/30/2026 | 1155582463 | CMS |
| ABBVIE INC. | $9.27 | 10/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103900708 | CMS |
| UCB, Inc. | $25.28 | 10/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143115843 | CMS |
| Novartis Pharmaceuticals Corporation | $18.36 | 10/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086783201 | CMS |
| ABBVIE INC. | $24.64 | 10/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103900706 | CMS |
| AstraZeneca Pharmaceuticals LP | $18.17 | 10/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104751128 | CMS |
| UCB, Inc. | $31.61 | 10/14/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143115841 | CMS |
| AstraZeneca Pharmaceuticals LP | $14.23 | 10/10/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104340656 | CMS |
| Aurinia Pharma U.S., Inc. | $22.82 | 10/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1150681817 | CMS |
| ABBVIE INC. | $16.15 | 10/07/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103900704 | CMS |
| ABBVIE INC. | $3,500.00 | 10/04/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103153972 | CMS |
| Alexion Pharmaceuticals, Inc. | $15.26 | 10/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1094018077 | CMS |
| Novartis Pharmaceuticals Corporation | $30.38 | 09/25/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086783189 | CMS |
| UCB, Inc. | $25.51 | 09/24/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143115839 | CMS |
| Novartis Pharmaceuticals Corporation | $18.50 | 09/23/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1086783187 | CMS |
| Janssen Biotech, Inc. | $3,850.00 | 09/21/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078530968 | CMS |
| ABBVIE INC. | $3.66 | 09/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103900702 | CMS |
| Janssen Biotech, Inc. | $198.32 | 09/19/2024 | Travel and Lodging | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078528223 | CMS |
| Janssen Biotech, Inc. | $6.59 | 09/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078530111 | CMS |
| Janssen Biotech, Inc. | $18.38 | 09/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078530712 | CMS |
| GENZYME CORPORATION | $20.40 | 09/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1139799060 | CMS |
| UCB, Inc. | $1.98 | 09/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143115835 | CMS |
| UCB, Inc. | $26.60 | 09/18/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143115837 | CMS |
| ABBVIE INC. | $0.47 | 09/17/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103900700 | CMS |
| ABBVIE INC. | $3,500.00 | 09/16/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103153970 | CMS |
| UCB, Inc. | $6.37 | 09/16/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143115833 | CMS |
| ABBVIE INC. | $20.71 | 09/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103900696 | CMS |
| ABBVIE INC. | $6.97 | 09/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103900698 | CMS |
| E.R. Squibb & Sons, L.L.C. | $14.29 | 09/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101630660 | CMS |
| UCB, Inc. | $27.18 | 09/12/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143115831 | CMS |
| Fresenius Kabi USA, LLC | $21.03 | 09/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1146952682 | CMS |
| Sandoz Inc. | $15.72 | 09/09/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1089369880 | CMS |
| AstraZeneca Pharmaceuticals LP | $24.95 | 09/04/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1104573804 | CMS |
| ABBVIE INC. | $23.75 | 09/03/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103900694 | CMS |
| ABBVIE INC. | $7.19 | 08/29/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103900692 | CMS |
| E.R. Squibb & Sons, L.L.C. | $22.02 | 08/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1101630652 | CMS |
| UCB, Inc. | $15.09 | 08/26/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143115829 | CMS |
| ABBVIE INC. | $3,500.00 | 08/23/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103153968 | CMS |
| ABBVIE INC. | $13.29 | 08/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103900688 | CMS |
| ABBVIE INC. | $84.06 | 08/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103900690 | CMS |
| Janssen Biotech, Inc. | $963.00 | 08/22/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078529976 | CMS |
| UCB, Inc. | $17.53 | 08/22/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143115827 | CMS |
| ABBVIE INC. | $3,500.00 | 08/21/2024 | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1103153966 | CMS |
| Amgen Inc. | $13.83 | 08/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1117274754 | CMS |
| UCB, Inc. | $10.96 | 08/21/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143115825 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.94 | 08/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1105444920 | CMS |
| UCB, Inc. | $20.36 | 08/20/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1143115823 | CMS |
| Janssen Biotech, Inc. | $112.75 | 08/19/2024 | Food and Beverage | No dispute reported | Delay: No Change: UNCHANGED | 06/30/2026 | 1078530979 | CMS |
By program year
All program years on this page · sorted by year
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-06-30
- Program years on this page
- 2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
- Source files
- Dataset page · Bulk file · PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024 , PY2025
- Generated from
- OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.
Research Payments
One row per program year and role, newest year first · amounts for the two roles are never added together
| Program year | Role | Amount | Records |
|---|---|---|---|
| PY2025 | Recipient | $770.81 | 1 |
| PY2025 | Principal investigator | $459,962.74 | 50 |
| PY2024 | Recipient | $28,555.27 | 2 |
| PY2024 | Principal investigator | $247,601.77 | 31 |
| PY2023 | Principal investigator | $254,095.35 | 58 |
| PY2022 | Principal investigator | $190,630.87 | 75 |
| PY2021 | Principal investigator | $30,012.95 | 21 |
Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.
“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”
— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224
Research Payments records · PY2025
Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them
51 records in PY2025
| Role | Paying entity | Amount | Date | Recipient | Study | Dispute status | Published | Record ID |
|---|---|---|---|---|---|---|---|---|
| Principal investigator 1 | Janssen Research & Development, LLC | $2,240.00 | 12/19/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175425642 |
| Principal investigator 1 | ABBVIE INC. | $500.00 | 12/18/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202531166 |
| Principal investigator 1 | ABBVIE INC. | $3,000.00 | 12/18/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202531180 |
| Principal investigator 1 | ABBVIE INC. | $2,400.00 | 12/18/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202531190 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $31.00 | 12/15/2025 | Non-covered Recipient Entity Rao Research Llc | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226128991 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $26.10 | 11/15/2025 | Non-covered Recipient Entity RHEUMATOLOGY ASSOCIATES OF OKLAHOMA | A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-2) | No dispute reported | 06/30/2026 | 1190308628 |
| Principal investigator 1 | ABBVIE INC. | $3,983.85 | 11/05/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202522865 |
| Principal investigator 1 | ABBVIE INC. | $3,137.00 | 10/09/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202515283 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $292.77 | 10/08/2025 | Non-covered Recipient Entity RHEUMATOLOGY ASSOCIATES OF OKLAHOMA | A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease | No dispute reported | 06/30/2026 | 1190308480 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $125.85 | 10/08/2025 | Non-covered Recipient Entity RHEUMATOLOGY ASSOCIATES OF OKLAHOMA | A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome | No dispute reported | 06/30/2026 | 1190308624 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 09/15/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175425607 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $565.84 | 09/15/2025 | Non-covered Recipient Entity Rao Research Llc | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226128886 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $225.00 | 09/15/2025 | Non-covered Recipient Entity Rao Research Llc | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226128890 |
| Principal investigator 1 | ABBVIE INC. | $6,375.00 | 09/04/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202508866 |
| Principal investigator 1 | ABBVIE INC. | $11,620.00 | 09/04/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | Program to Assess Adverse Events and Change in Disease Activity of Oral Upadacitinib in Adult Participants With Moderate to Severe Systemic Lupus Erythematosus (SELECT-SLE) | No dispute reported | 06/30/2026 | 1202508868 |
| Principal investigator 1 | ABBVIE INC. | $1,811.00 | 09/03/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202507393 |
| Principal investigator 1 | Amgen Inc. | $291.65 | 08/26/2025 | Non-covered Recipient Entity RHEUMATOLOGY ASSO.OF OKLAHOMA | A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Dazodalibep in Participants With Sjgrens Syndrome With Moderate-to-Severe Systemic Disease Activity | No dispute reported | 06/30/2026 | 1246647321 |
| Principal investigator 1 | ABBVIE INC. | $1,941.00 | 08/05/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202501232 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $325.00 | 07/14/2025 | Non-covered Recipient Entity Rao Research Llc | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226128836 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,368.00 | 07/07/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175425636 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,257.50 | 07/02/2025 | Non-covered Recipient Entity Rao Research Llc | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226128839 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $3,000.00 | 06/16/2025 | Non-covered Recipient Entity Rao Research Llc | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226128768 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $910.00 | 06/09/2025 | Non-covered Recipient Entity Rao Research Llc | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226128755 |
| Principal investigator 1 | ABBVIE INC. | $6,741.00 | 06/03/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202489727 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $880.00 | 06/03/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-2) | No dispute reported | 06/30/2026 | 1190311853 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 06/02/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175425627 |
| Principal investigator 1 | Janssen Research & Development, LLC | $500.00 | 06/02/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175425633 |
| Principal investigator 1 | Janssen Research & Development, LLC | $1,200.00 | 05/23/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175425617 |
| Principal investigator 1 | ABBVIE INC. | $65.00 | 05/22/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202485851 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,200.00 | 05/19/2025 | Non-covered Recipient Entity Rao Research Llc | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226128784 |
| Principal investigator 1 | ABBVIE INC. | $2,500.00 | 05/15/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202485059 |
| Principal investigator 1 | ABBVIE INC. | $1,470.00 | 05/15/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202485061 |
| Principal investigator 1 | ABBVIE INC. | $6,858.00 | 05/06/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202481761 |
| Recipient | Eli Lilly and Company | $770.81 | 04/23/2025 | Covered Recipient Physician | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | No dispute reported | 06/30/2026 | 1187871067 |
| Principal investigator 1 | Janssen Research & Development, LLC | $26,559.00 | 04/17/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Evaluating the Efficacy and Safety ofJNJ-77242113 for the Treatment of Biologic-experienced Participants with Active Psoriatic Arthritis | No dispute reported | 06/30/2026 | 1175425612 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,857.50 | 04/14/2025 | Non-covered Recipient Entity Rao Research Llc | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226128720 |
| Principal investigator 1 | ABBVIE INC. | $1,941.00 | 04/03/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202473554 |
| Principal investigator 1 | Eli Lilly and Company | $294.00 | 04/03/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | No dispute reported | 06/30/2026 | 1187888722 |
| Principal investigator 1 | Janssen Research & Development, LLC | $2,520.00 | 03/31/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent | No dispute reported | 06/30/2026 | 1175425622 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $7,507.50 | 03/17/2025 | Non-covered Recipient Entity Rao Research Llc | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226128690 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $6,305.00 | 02/24/2025 | Non-covered Recipient Entity Rao Research Llc | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226128621 |
| Principal investigator 1 | Eli Lilly and Company | $54,117.79 | 02/11/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) | No dispute reported | 06/30/2026 | 1187887922 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $19,900.95 | 02/10/2025 | Non-covered Recipient Entity RHEUMATOLOGY ASSOCIATES OF OKLAHOMA | A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome | No dispute reported | 06/30/2026 | 1190308626 |
| Principal investigator 1 | ABBVIE INC. | $1,941.00 | 02/05/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | M23-700 - Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib Compared to Subcutaneous Adalimumab in Adult Participants With Moderate to Severe Rheumatoid Arthritis (SELECT- SWITCH) | No dispute reported | 06/30/2026 | 1202445726 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $156,247.24 | 01/28/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease | No dispute reported | 06/30/2026 | 1190311849 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $26,954.00 | 01/28/2025 | Non-covered Recipient Entity RAO RESEARCH LLC | A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome | No dispute reported | 06/30/2026 | 1190311851 |
| Principal investigator 1 | E.R. Squibb & Sons, L.L.C. | $4,549.59 | 01/21/2025 | Non-covered Recipient Entity Rheumatology Associates Of Oklahoma | A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Nave to Biologic Disease Modifying Anti-rheumatic Drugs or Had Previously Received TNF Inhibitor Treatment | No dispute reported | 06/30/2026 | 1235994227 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $4,420.00 | 01/21/2025 | Non-covered Recipient Entity Rao Research Llc | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226128635 |
| Principal investigator 1 | SANOFI US SERVICES INC. | $155.00 | 01/21/2025 | Non-covered Recipient Entity Rao Research Llc | Efficacy and Safety of SAR441344 in the Treatment of Systemic Lupus Erythematosus: A Randomized, Double Blind, Placebo-controlled, Phase 2, Proof of Concept Study | No dispute reported | 06/30/2026 | 1226128702 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $2,260.50 | 01/15/2025 | Non-covered Recipient Entity RHEUMATOLOGY ASSOCIATES OF OKLAHOMA | A Randomized, Double-blind, Placebo Controlled, 3-arm Multicenter Phase 3 Study to Assess the Efficacy and Safety of Ianalumab in Patients With Active Sjogren's Syndrome (NEPTUNUS-2) | No dispute reported | 06/30/2026 | 1190308630 |
| Principal investigator 1 | Novartis Pharmaceuticals Corporation | $63,592.11 | 01/09/2025 | Non-covered Recipient Entity RHEUMATOLOGY ASSOCIATES OF OKLAHOMA | A Randomized, Two-period Crossover Study to Demonstrate the Comparability of Pharmacokinetics of Subcutaneous Ianalumab Between 2mL Auto-injector/2mL Pre-filled Syringe With 1 mL Pre-filled Syringe in Adult Participants With Autoimmune Disease | No dispute reported | 06/30/2026 | 1190308482 |